Please use this identifier to cite or link to this item:
Title: Safety and Efficacy of Single vs Dual Antiplatelets Therapy After Atrial Septal Defect Device Closure
Authors: Adhikari, Chandra Mani
Prajapati, Dipanker
Bogati, Amrit
Acharya, Kiran Prasad
Acharya, Anjana
Shahi, Roshani
Shrestha, Swikirty
Ghimire, Vijay
Thapa, Kavindra
Sherpa, Kunjang
Citation: AdhikariC. M., PrajapatiD., BogatiA., AcharyaK. P., AcharyaA., ShahiR., ShresthaS., GhimireV., ThapaK., & SherpaK. (2021). Safety and Efficacy of Single vs Dual Antiplatelets Therapy After Atrial Septal Defect Device Closure. Journal of Nepal Health Research Council, 19(2), 295-299.
Issue Date: 2021
Publisher: Nepal Health Research Council
Keywords: Atrial septal defect
ASD device closure
Series/Report no.: Apr-June, 2021;3477
Abstract: Abstract Background: Atrial septal defect device closure has become a standard procedure. Antiplatelet therapy is used to prevent thrombus formation in the device. There is no clear recommendation about the antiplatelets drugs. This study aims to evaluate the safety and efficacy of Aspirin vs (Aspirin +Clopidogrel) after device closure. Methods: A cross-sectional study was conducted among all consecutive adult patients (?18 years) who underwent atrial septal defect device closure from May 2019 to April 2020 and meet the inclusion criteria were included. After successful ASD device closure patients were treated with ASA or combination of ASA and Clopidogrel for six months on physician discretion. Patients were followed up for six months to observe for Transient ischemic attack, Stroke, thrombus in the device, myocardial infarction, major bleeding, minor bleeding and increases in headache episodes compared to baseline. Results: This study consisted of 130 patients: 65 in the Aspirin Group, and 65 patients in Aspirin and Clopidogrel group. There was no Transient ischemic attack, Stroke, Myocardial infarction, thrombus, major bleeding in both groups. There was no significant difference between two groups in ecchymosis; Aspirin group 4(6.1%) vs. aspirin and Clopidogrel group 3(4.6%) [Difference, 1.54% {95, % CI, -1.45%to 4.53%}]; P=0.648. There was no significant difference in increase in headache episodes compared to baseline for six months after the device closure in Aspirin Group 3(4.6%) VS Aspirin and Clopidogrel group 2 (3.0%) group [difference, 1.54% {95% CI, -1.45%to 4.53%}]; P=0.648. Conclusions: Our study suggests that single antiplatelet therapy with Aspirin is as safe and effective as aspirin and clopidogrel after device closure. Keywords: Atrial septal defect; ASD device closure; clopidogrel
Description: Original Article
ISSN: Print ISSN: 1727-5482; Online ISSN: 1999-6217
Appears in Collections:Vol. 19 No. 2 (2021): Vol 19 No 2 Issue 51 Apr-Jun 2021

Files in This Item:
File Description SizeFormat 
3477-Manuscript-23767-1-10-20210907.pdfFulltext Download215.3 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.